Polly Niravath
Overview
Explore the profile of Polly Niravath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodin D, Chau E, Zheng J, OConnell C, Tiwari A, Xu Y, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2846-2857.
PMID: 39373616
Significance: BCLM tissue characterization to optimize immunotherapy is difficult because biopsies or resections are rarely performed. This study shows that a machine learning approach offers the potential to infer BCLM...
2.
Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, et al.
Clin Cancer Res
. 2022 Jul;
28(20):4392-4401.
PMID: 35877117
Purpose: A Phase 2 trial of stereotactic radiotherapy and in situ cytotoxic virus therapy in patients with metastatic triple-negative breast cancer (mTNBC) followed by pembrolizumab (STOMP) was designed to evaluate...
3.
Puri A, Mylavarapu C, Xu J, Patel T, Teh B, Tremont-Lukats I, et al.
Breast Cancer Res Treat
. 2022 Apr;
193(3):613-623.
PMID: 35460498
Purpose: Leptomeningeal metastases (LM) are an aggressive complication of metastatic breast cancer (MBC) with brain metastases (BM), with a short survival of weeks to months. Studies suggest that surgical resection...
4.
Chatham M, Niravath P
Cureus
. 2022 Jan;
13(12):e20203.
PMID: 35004023
Anti-Yo-associated paraneoplastic cerebellar degeneration (PCD) syndrome is a very rare condition that is most commonly associated with breast and gynecologic cancers. Those cases associated with breast cancer tend to be...
5.
Anand K, Niravath P, Patel T, Ensor J, Rodriguez A, Boone T, et al.
Clin Breast Cancer
. 2021 Jun;
21(3):199-204.
PMID: 34159901
Introduction: Chemotherapy eliminates most of the cancer cells except those with potential for self-renewal and tumor initiation, called cancer stem cells (CSCs). Chloroquine, through bioinformatics, was found to be a...
6.
Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, et al.
Oncologist
. 2021 Feb;
26(6):e936-e942.
PMID: 33594769
Purpose: This study evaluated the proportion of premenopausal women who experience persistent ovarian escape (OE) while receiving ovarian suppression (OS) therapy for estrogen receptor-positive (ER+) breast cancer treatment. The study...
7.
Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, et al.
Sci Rep
. 2021 Jan;
11(1):82.
PMID: 33420229
Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the...
8.
Umoru G, Taitano M, Beshay S, Niravath P, Sahay S
ERJ Open Res
. 2020 Jul;
6(2).
PMID: 32714960
https://bit.ly/2X90xDu.
9.
Polamraju P, Haque W, Cao K, Verma V, Schwartz M, Klimberg V, et al.
Breast
. 2019 Nov;
49:8-16.
PMID: 31675684
Purpose: Metaplastic breast cancer (MBC) is a rare, aggressive variant of breast cancer that has been associated with poor clinical outcomes, as has triple-negative breast (TNBC) cancer. Limited studies compare...
10.
Rimawi M, Niravath P, Wang T, Rexer B, Forero A, Wolff A, et al.
Clin Cancer Res
. 2019 Oct;
26(4):821-827.
PMID: 31662331
Purpose: Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we...